Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Relypsa Inc Announces Pricing Of Initial Public Offering


Thursday, 14 Nov 2013 11:45pm EST 

Relypsa Inc announced the pricing of its initial public offering of 6,850,000 shares of its common stock at a price to the public of $11.00 per share. The shares are expected to begin trading on The NASDAQ Global Select Market on November 15, 2013 under the ticker symbol "RLYP." All of the shares of common stock are being offered by Relypsa. In addition, Relypsa has granted the underwriters a 30-day option to purchase up to an additional 1,027,500 shares of common stock to cover over-allotments, if any. Relypsa estimates net proceeds from the offering to be approximately $67.4 million (assuming no exercise of the underwriters' over-allotment option), after deducting underwriting discounts and commissions and estimated offering expenses. Relypsa expects to close its initial public offering on or about November 20, 2013, subject to satisfaction of customary closing conditions. Morgan Stanley & Co. LLC, BofA Merrill Lynch and Cowen and Company are acting as joint book-running managers for the offering. Stifel and Wedbush PacGrow Life Sciences are acting as co-managers. 

Latest Key Developments in Pharmaceuticals